The Effect of Hypericum Perforatum on Depression Treatment: A Review

Öz

In many countries of the world, complementary medicine is used as a treatment in mental health diseases. The mechanism of its action is similar to that of antidepressants, but the lack of side effects leads to more interest in complementary medicines day by day. The purpose of this article is the collection and compilation of the data obtained from the literature studies on the treatment of depression with St. John's wort. In this context, 29 articles have been examined by using Science Direct, Pubmed and Google Scholar databases and international journals and publications on the effects of John’s wort on depression have been compiled. When the studies on the effects of John’s wort on the treatment of depression were examined, it was concluded that they were effective in the treatment of mild and moderate depression. Even in some studies, they were compared with antidepressants and they were found to be as effective as them. As a result; St. John's wort is effective in patients with mild to moderate depression symptoms but should be used under the supervision and the permission of a doctor

Anahtar Kelimeler

• Depression
• Hypericum Perforatum
• Phytotherapy
• St John

Hypericum Perforatum’un Depresyon Tedavisi Üzerine Etkisi: Bir Gözden Geçirme

Öz

Dünyanın birçok ülkesinde tamamlayıcı tıp, ruh sağlığı hastalıklarının tedavisinde kullanılmaktadır. Etki mekanizmalarının antidepresanlarla benzer olması fakat antidepresanlar kadar yan etkilerinin olmaması tamamlayıcı tıbba ilgiyi artırmaktadır. Bu makalenin amacı; sarı kantaronun depresyon tedavisi üzerine etkisinin literatür çalışmalarından elde edilen veriler toplanarak derlenmesi ve bu verilerin ilişkilendirilmesidir. Bu bağlamda, Science Direct, Pubmed ve Google Scholar veri tabanları ve uluslararası dergilerden faydalanılarak 29 makale incelenmiş ve sarı kantaronun depresyon tedavisindeki etkisi üzerine yazılan yayınlar derlenmiştir. Sarı kantaronun depresyon tedavisindeki etkileri üzerine yapılan çalışmalar incelendiğinde özellikle hafif ve orta düzey depresyonun tedavisinde etkili oldukları sonucuna varılmıştır. Hatta bazı çalışmalarda, antidepresan ile karşılaştırma yapılmış ve antidepresan kadar etkili olduğu bulunmuştur. Sonuç olarak; sarı kantaronun hafif ve orta düzey depresyon belirtileri olan hastalarda etkili olduğu, doktor izni ile doktor gözetimi altında kullanılabileceği söylenilebilir.

Anahtar Kelimeler

• Depresyon
• Fitoterapi
• Hypericum Perforatum

Kaynakça

1. Haller, H., Anheyer, D., Cramer, H., & Dobos, G. (2019). Complementary therapies for clinical depression: an overview of systematic reviews. BMJ open, 9(8), e028527.
2. Kessler, R.C.; Soukup, J.; Davis, R.B.; Foster, D.F.; Wilkey, S.A.; Van Rompay, M.I.; Eisenberg, D.M. Th e use of complementary and alternative therapies to treat anxiety and depression in the United States. Am. J. Psychiatry 2001, 158, 289–294.
3. Hansen, A.H.; Kristoff ersen, A.E. Th e use of CAM providers and psychiatric outpatient services in people with anxiety/depression: A cross-sectional survey. BMC Complement. Altern. Med. 2016, 16, 461.
4. Druss, B.G.; Rosenheck, R.A. Use of practitioner-based complementary therapies by persons reporting mental conditions in the United States. Arch. Gen. Psychiatry 2000, 57, 708–714.
5. Armour, M., Smith, C. A., Wang, L. Q., Naidoo, D., Yang, G. Y., MacPherson, H., ... & Hay, P. (2019). Acupuncture for depression: a systematic review and meta-analysis. Journal of clinical medicine, 8(8), 1140.
6. Shelton RC. St John’s wort (Hypericum perforatum) in major depression. Th e Journal of clinical psychiatry. 2009; 70: 23-27.
7. Ji, X., Ivers, H., Beaulieu-Bonneau, S., & Morin, C. M. (2021). Complementary and alternative treatments for insomnia/insomnia-depression-anxiety symptom cluster: Meta-analysis of English and Chinese literature. Sleep Medicine Reviews, 101445.
8. Alternative Medicine Review. Hypericum Perforatum Monograph. 2004; 9(3): 318-325. Erişim 13.05.2020, https://studyres.com/doc/7117045/hypericum-perforatum-monograph.

9. Bilia AR, Gallori S, Vincieri FF. St. John’s wort and depression: eff icacy, safety and tolerability-an update. Life sciences. 2002; 70(26): 3077-3096.
10. Kaçar O, Azkan N. Bursa’da Doğal Florada Bulunan Sarı Kantaron (Hypericum Perforatum L.) Populasyonlarında Farklı Yüksekliklerin Hiperisin Oranı Üzerine Etkisinin Belirlenmesi. Uludağ Üniversitesi Ziraat Fakültesi Dergisi. 2005; 19(1): 77-89.
11. Çakmak HE, Bayram E. Muğla Orijinli Sarı Kantaron (Hypericum Perforatum L.) Populasyonlarının Bazı Agronomik Ve Kalite Özelliklerinin Belirlenmesi. Ege Üniversitesi Ziraat Fakültesi Dergisi. 2003; 40(1).
12. Wurglics M, Schubert-Zsilavecz M. Hypericum perforatum: A ‘modern’herbal antidepressant. Clinical pharmacokinetics. 2006; 45(5): 449-468.
13. Butterweck V, Liefl ander-Wulf U, Winterhoff H, et al. Plasma levels of hypericin in presence of procyanidin B2 and hyperoside: a pharmacokinetic study in rats. Planta Med 2003; 69 (3): 189-92
14. Calapai G, Crupi A, Firenzuoli F, et al. Serotonin, norepinephrine and dopamine involvement in the antidepressant action of hypericum perforatum. Pharmacopsychiatry, 2001; 34(02): 45-49.
15. Whiskey E, Werneke U, Taylor D. A systematic review and meta-analysis of Hypericum perforatum in depression: a comprehensive clinical review. International clinical psychopharmacology. 2001; 16(5): 239-252.
16. Greeson JM, Sanford B, Monti DA. St. John’s wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology. 2001; 153(4): 402-414.
17. Shelton RC, Keller MB, Gelenberg A, et al. Eff ectiveness of St John’s wort in major depression: a randomized controlled trial. Jama. 2001; 285(15): 1978-1986.
18. Moreno RA, Teng CT, Almeida KMD, Tavares Junior H. Hypericum perforatum versus fl uoxetine in the treatment of mild to moderate depression: a randomized double-blind trial in a Brazilian sample. Brazilian Journal of Psychiatry. 2006; 28(1): 29-32.
19. Linde K, Berner M, Egger M, Mulrow C. St John’s wort for depression: meta-analysis of randomised controlled trials. Th e British Journal of Psychiatry. 2005; 186(2): 99-107.
20. Hypericum Depression Trial Study Group. Eff ect of Hypericum perforatum (St John’s wort) in major depressive disorder: a randomized controlled trial. Jama. 2002; 287(14): 1807- 1814.
21. Woelk H. Comparison of St John’s wort and imipramine for treating depression: randomised controlled trial. Bmj. 2000; 321(7260): 536-539.
22. Hübner WD, Kirste T. Experience with St John’s Wort (Hypericum perforatum) in children under 12 years with symptoms of depression and psychovegetative disturbances. Phytotherapy Research. 2001; 15(4): 367-370.
23. Cervo L, Rozio M, Ekalle-Soppo C, Guiso G, Morazzoni P, Caccia S. Role of hyperforin in the antidepressant-like activity of Hypericum perforatum extracts. Psychopharmacology. 2002; 164(4): 423-428.
24. Szegedi A, Kohnen R, Dienel A, Kieser M. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John’s wort): randomised controlled double blind non-inferiority trial versus paroxetine. Bmj. 2005; 330(7490): 503.
25. Fava M, Alpert J, Nierenberg AA, et al. A Double-blind, randomized trial of St John’s wort, fl uoxetine, and placebo in major depressive disorder. Journal of clinical psychopharmacology. 2005; 25(5): 441-447.
26. Brattström, A. Long-term eff ects of St. John’s wort (Hypericum perforatum) treatment: A 1-year safety study in mild to moderate depression. Phytomedicine. 2009; 16(4): 277-283.
27. Husain GM, Chatterjee SS, Singh PN, Kumar VIKAS. Beneficial eff ect of Hypericum perforatum on depression and anxiety in a type 2 diabetic rat model. Acta Pol Pharm. 2011; 68(6), 913-918.
28. Sarris J, Fava M, Schweitzer I, Mischoulon D. St John’s wort (Hypericum perforatum) versus sertraline and placebo in major depressive disorder: continuation data from a 26-week RCT. Pharmacopsychiatry. 2012; 45(07): 275-278.
29. Kasper S, Caraci F, Forti B, Drago F, Aguglia E. Eff icacy and tolerability of Hypericum extract for the treatment of mild to moderate depression. European Neuropsychopharmacology. 2010; 20(11): 747-765.